Name: Inhaled treprostinil in PH-ILD: The INCREASE study
Uploaded: 2023-10-19T00:00:00.0000000
Duration: T00H01M59S
Description: Inhaled treprostinil in PH-ILD: The INCREASE study

Name: Inhaled treprostinil in PH-ILD: The INCREASE study

Description: Inhaled treprostinil in PH-ILD: The INCREASE study

Thumbnail URL: https://cadmoremediastorage.blob.core.windows.net/f10c827e-ae63-4c03-a766-011179b70623/thumbnails/f10c827e-ae63-4c03-a766-011179b70623.png

Duration: T00H01M59S

Embed URL: https://stream.cadmore.media/player/f10c827e-ae63-4c03-a766-011179b70623

Content URL: https://cadmoreoriginalmedia.blob.core.windows.net/f10c827e-ae63-4c03-a766-011179b70623/FSG - INCREASE - Animation V10 (1).mp4?sv=2019-02-02&sr=c&sig=MjOITdqgpoZJhfJsfZ7kDmnDanSczUlvq8W3Xov5O%2BA%3D&st=2024-11-21T09%3A19%3A43Z&se=2024-11-21T11%3A24%3A43Z&sp=r

Upload Date: 2023-10-19T00:00:00.0000000

Transcript: Language: EN.
Segment:0 .
People with pulmonary hypertension have high blood pressure in their lungs. In interstitial lung disease, lung tissue becomes scarred and inflamed, making breathing difficult. ILD includes many different diseases, such as idiopathic pulmonary fibrosis. Pulmonary hypertension can accompany interstitial lung disease and is more common in patients with advanced disease. PH-ILD is a rare, serious, and progressive condition. Treprostinil is used to treat a similar disease called pulmonary arterial hypertension. Inhaling treprostinil delivers it directly to the lungs to help keep blood vessels open and improve blood flow.
Before the INCREASE study, there were no FDA-approved drugs to treat PH-ILD. The study aimed to see if Treprostinil could help people with PH-ILD. Patients received the drug or placebo four times daily. As PH-ILD causes breathing problems and tiredness, researchers wanted to test if inhaling treprostinil would help patients increase their ability to walk farther. This is a clinical test that helps measure how well the heart and lungs are working by measuring walking distance in 6 minutes.
At the start of the study, all participants walked a similar distance. After 16 weeks, the treatment group increased their six-minute walking distance by an average 31 metres (102 feet) more than the placebo group. Study participants are required to report any medical problems. In this study, the treatment group reported side effects, such as coughing, headache, and sore throat more often than the placebo group. The FDA approved inhaled treprostinil as the first treatment for PH-ILD, based on INCREASE study findings.

Cadmore media player playing video Inhaled treprostinil in PH-ILD: The INCREASE study

Video Player

Transcript

Segments

End of Video Player Control